Lexaria BioScience (OTCQX: LXRP- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver with news the company has seen their Phase One research and development program of oral forms of nicotine delivery finish with Altria Ventures.
Bunka says everything went as planned and now Altria has exercised its right to activate the "First Warrant Tranche Trigger and now has 90 days to provide that payment to retain its current exclusivity in the US market for DehydraTECH.
CSE:LXX
Market: CSE
Market Cap: $35.83 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Lexaria Bioscience seeing increased demand for its DehydraTECH drug...
Most read
Full interview: Lexaria Bio Science files patent for technology to treat...
Lexaria Bioscience (CSE: LXX-OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to discuss the company has filed a patent for their DehydraTech technology for the delivery of antiviral drugs. Bunka telling Proactive this technology would potentially be used to improve...
on 04/21/2020
2 min read
Prev article
4 min read